NHS National Framework for Transition products commencing 1 May 2024
Who
| Buyer | NHS ENGLAND — not a council we hold |
| Supplier | Aspire Pharma Limited |
| Supplier | Celix Pharma Ltd. |
| Supplier | Dr.Reddy's Laboratories (UK) Limited |
| Supplier | Glenmark Pharmaceuticals Europe Limited |
| Supplier | Immedica Pharma AB |
| Supplier | Kent Pharma Ltd |
| Supplier | LogixX Pharma Ltd |
| Supplier | Mylan |
| Supplier | Sandoz Ltd |
| Supplier | Selective Supplies Ltd. |
| Supplier | Teva UK Limited |
| Supplier | Thornton and Ross Ltd |
What
Project title: NHS National Framework for Transition products commencing 1 May 2024 Offer reference number: CM/TNS/05/2024 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/05/2024/01 - Dimethyl fumarate, Teriflunomide, Trabectedin Lot 1 NWLN: 01/05/2024 to 31/01/2025 (9 months) Lot 2 CESW: 01/05/2024 to 30/09/2025 (17 months) Lot 3 LSNE: 01/05/2024 to 30/09/2025 (17 months) CM/TNS/05/2024/02 - Apixaban, Sapropterin Lot 1 DNW+DNE+DCE 01/05/2024 to 30/09/2025 (17 months) Lot 2 DLS+DLN+DSW 01/05/2024 to 30/09/2025 (17 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Dates and source
| Runs | 1 May 2024 to 30 Sep 2025 |
| OCID | ocds-b5fd17-c543315b-95e4-4921-9db4-3e85671128a1 |
| Notice | Read it on Contracts Finder |
Figures are as published An award value in OCDS may be a framework ceiling rather than a sum anyone expects to spend, so a large figure here is not evidence of a large purchase.